Scarica l'app Stockscreener
55.04
1.10%
-0.66
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CRSP Giù?
Forum
Previsione
Crispr Therapeutics Ag Borsa (CRSP) Ultime notizie
CRISPR Therapeutics' General Counsel James R. Kasinger Sells 10,400 Shares Following Option Exercise - Kalkine Media
Form 4 CRISPR Therapeutics AG For: 24 September By Investing.com - Investing.com Nigeria
CRISPR Therapeutics (NASDAQ:CRSP) General Counsel James Kasinger Sells 10,400 Shares of Company Stock - MarketBeat
CRISPR Therapeutics (CRSP) counsel exercised options and sold 10,400 shares under a trading plan. - Stock Titan
CRISPR Therapeutics' Casgevy sales jump 78% in Q2, boosting long-term buy case despite AI gene editing risks - Pluang
Crispr Therapeutics: Why AI Giant Anthropic's Discovery Has Rocked Gene Editing (CRSP) - Seeking Alpha
CRISPR Therapeutics AG (CRSP) stock price, news, quote and history - Yahoo Finance Singapore
CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
CRISPR Therapeutics AG (CRSP) Stock Price, News, Quote & History - Yahoo! Finance Canada
CRISPR Therapeutics (CRSP) Shares Dip Amid Anthropic AI Enzyme D - gurufocus.com
Gene editing stocks fall after Anthropic’s CRISPR-like discovery - Seeking Alpha
CRISPR Therapeutics AG (CRSP) Options ChainYahoo Finance - Yahoo! Finance Canada
Autologous Hematopoietic Stem Cell Gene Therapy Market - GlobeNewswire
Autologous Hematopoietic Stem Cell Gene Therapy Market Global Report 2026: A $13.44 Billion Market by 2030 as Novartis, Vertex, CRISPR Therapeutics and Orchard Therapeutics Accelerate the Gene-Editing Race - Yahoo Finance UK
What Put the CRISPR Therapeutics (CRSP) Story on the Radar? - Kalkine Media
CRISPR Therapeutics AG (CRSP) Stock Moves 1.20%: What You Should Know - Yahoo Finance
Insider plans $626K CRISPR Therapeutics (NASDAQ: CRSP) stock sale - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Ali Behbahani Sells 13,679 Shares of CRISPR Therapeutics (NASDAQ:CRSP) Stock - MarketBeat
CRISPR Therapeutics (CRSP) director exercises options, then sells 13,679 shares around $57 - Stock Titan
Director at CRISPR Therapeutics (CRSP) gets stock in no-cash fund distribution - Stock Titan
Why CRISPR Therapeutics (CRSP) Is Back In The Spotlight - simplywall.st
New Treatment Cuts “Bad” Cholesterol in Half for a Full Year - SciTechDaily
CRISPR Therapeutics stock edges lower as investors digest latest pipeline and earnings figures - AD HOC NEWS
3 Reasons CRISPR Therapeutics Stock Is Still a Buy After a Rocky 2026 - The Motley Fool
CRISPR Therapeutics AG (CRSP) Stock Forecasts - Yahoo Finance
Can Intellia's Pipeline Progress Create Long-Term Value Amid Rivalry? - TradingView
Where Will CRISPR Therapeutics Be in 10 Years if Gene Editing Fulfills Its Promise? - The Motley Fool
CRISPR Therapeutics (NASDAQ:CRSP): What's Behind Its Stock Surge? - Kalkine Media
Director at CRISPR Therapeutics (NASDAQ: CRSP) files notice for six-figure stock sale - Stock Titan
CRISPR Therapeutics (NASDAQ:CRSP) Shares Up 11.6%What's Next? - MarketBeat
CRISPR Therapeutics Surges 11.39% as CRSP Stock Breaks Above $58RSI Oversold Picks - careplusvn.com
Wall Street Analysts Think CRISPR Therapeutics (CRSP) Is a Good Investment: Is It? - Yahoo Finance
CRISPR Therapeutics (CRSP) Stock Looks Above Fair Value On Book Value - simplywall.st
CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
CRISPR Therapeutics Eyes CASGEVY Growth, Year-End Pipeline Catalysts - Yahoo Finance
AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
4 Best CRISPR Companies to Buy in 2026 and How to Invest - The Motley Fool
Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Axsome Therapeutics vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
GOOG: Alphabet IncOrdinary SharesClass C Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
CRISPR Therapeutics (CRSP) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
Trading Systems Reacting to (CRSP) Volatility - Stock Traders Daily
Why CRISPR Therapeutics Stock Rocked the Market Last Month - The Motley Fool
CRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference - markets.businessinsider.com
Where Will CRISPR Therapeutics Stock Be in 5 Years? - The Motley Fool
Morgan Stanley's healthcare conference will feature CRISPR Therapeutics on Sept. 14 - Stock Titan
Raiffeisen Bank International AG Buys Shares of 20,000 CRISPR Therapeutics AG $CRSP - MarketBeat
0.39%
0.28%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):